Results 131 to 140 of about 10,558,921 (293)

Applying computational protein design to therapeutic antibody discovery - current state and perspectives

Frontiers in Immunology
Machine learning applications in protein sciences have ushered in a new era for designing molecules in silico. Antibodies, which currently form the largest group of biologics in clinical use, stand to benefit greatly from this shift.
Weronika Bielska, Weronika Bielska, Igor Jaszczyszyn, Igor Jaszczyszyn, Pawel Dudzic, Bartosz Janusz, Dawid Chomicz, Sonia Wrobel, Victor Greiff, Victor Greiff, Ryan Feehan, Jared Adolf-Bryfogle, Konrad Krawczyk   +12 more
doaj   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

AI-driven innovation in antibody-drug conjugate design

Frontiers in Drug Discovery
Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to antigen-expressing carcinoma cells.
Heather A. Noriega, Xiang Simon Wang
doaj   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Large scale paired antibody language models.

PLoS Computational Biology
Antibodies are proteins produced by the immune system that can identify and neutralise a wide variety of antigens with high specificity and affinity, and constitute the most successful class of biotherapeutics.
Henry Kenlay, Frédéric A Dreyer, Aleksandr Kovaltsuk, Dom Miketa, Douglas Pires, Charlotte M Deane   +5 more
doaj   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

A study of antibody secretion from hybridoma cells [PDF]

, 1988
The secretion of monoclonal antibody in both batch and continuous cultures was studied. It was found that when hybridoma cells were continuously cultivated in a simple lab scale fermenter, they secreted less antibody than cells grown in stationary ...
Holland, P.N.
core  

Antibody production in transgenic plants

, 2022
S.301-318Antibodies bind with great affinity and specificity to their target antigens, allowing them to be exploited in research, medicine, agriculture, and industry.
Christou, P., Twyman, R.M., Fischer, R., Stoger, E., Schillberg, S.   +4 more
core  

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity

Journal for ImmunoTherapy of Cancer
Background The paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell therapy of solid tumors necessitates careful preclinical evaluation of the therapeutic window for candidate antigens.
Stanley R Riddell, Ekram A Gad, Sylvain Simon, Tamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, Kristen R Shimp, Brandon W Seaton, Carla A Jaeger-Ruckstuhl, Amanda L Koehne, Jason P Price, James M Olson, Benjamin G Hoffstrom, David Jellyman   +13 more
doaj   +1 more source